

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Dermato-Venereologica

Table SI. Multiple regression analyses to search for predictors of the DLQI at baseline (month 0).

	Estimate	Standard Error	T-value	p-value
Intercept	15.62	2.22	7.02	<0.001
Age	-0.09	0.02	-3.32	0.001
Sex	2.37	0.84	2.79	0.005
PASI	0.26	0.06	3.82	<0.001
BMI	-0.11	0.07	-1.62	0.106
duration of psoriasis	-0.02	0.03	-0.77	0,441

PASI Psoriasis Area Severity Index, BMI body mass index.

Table SII. Most prevalently used biologic treatment options between 2011 and 2022 in the SDNTT registry.

Year	TNF-alpha	IL-17	IL-23	IL-12/23	p-value
2011	4	0	0	3	>0.999
2012	29	0	0	13	>0.999
2013	39	0	0	22	>0.999
2014	20	0	0	11	>0.999
2015	11	16	0	7	0.698
2016	10	15	0	15	0.999
2017	16	15	0	7	0.997
2018	3	15	0	6	0.011
2019	2	15	20	4	<0.001
2020	3	9	18	0	<0.001
2021	6	14	25	0	<0.001
2022	0	9	15	0	<0.001

Two-proportion Z-test applied to evaluate yearly treatment usage trends.

Table SIII. Descriptive statistics considering DLQI between young and old patient group

		Number of patients	Mean	Standard dev	Minimum	1st quantile	Median	3rd quantile	Maximum
≥65 years	Visit 1	87	8,89	6,41	0	3	8	12,5	27
	Visit 2	64	3,50	4,19	0	0	2	5	22
	Visit 3	47	2,59	3,17	0	0	1	4	13
	Visit 4	36	1,83	2,52	0	0	1	2	11
	Visit 5	25	1,52	2,18	0	0	1	2	9
	Visit 6	17	2,23	2,30	0	0	2	3	8
18 – 64 years	Visit 1	660	12,01	7,57	0	6	11	17	30
	Visit 2	515	4,51	5,41	0	0	2	7	27
	Visit 3	439	3,19	4,68	0	0	1	5	25
	Visit 4	330	2,64	4,40	0	0	1	3	29
	Visit 5	240	2,12	3,18	0	0	1	3	16
	Visit 6	213	2,31	3,84	0	0	1	3	24

Table SIV. Kruskal Wallis test comparing significant difference of the DLQI between young (18 – 64 years) and old (≥ 65 years) females and males.

	Number of old patients (>65 years)	Median DLQI	Number of young patients (18 - 64 years)	Median DLQI	p-value
Month 0	87	8	660	11	<0.001
Month 3	64	2	515	2	0.3
Month 6	47	1	439	1	0.9
Month 12	36	1	330	1	0.7
Month 18	25	1	240	1	0.9
Month 24	17	2	213	1	0.3

DLQI Dermatology Life Quality Index.

Table SV. Dermatology Life Quality Index (DLQI) at 3, 6, 12, 18 and 24 months.

	Number of male patients	Median DLQI	Number of female patients	Median DLQI	p-value
Month 0	470	10	278	13	<0.001
Month 3	371	2	208	3	0.2
Month 6	328	1	159	1	0.7
Month 12	240	1	126	1	0.5
Month 18	174	1	91	1	0.1
Month 24	154	1	76	1	0.059

Table SVI. Median Dermatology Life Quality Index (DLQI) at 0, 3, 6, 12, 18 and 24 months by treatment.

	Non-biologic treatments			TNF- α inhibitors			IL-17 inhibitors		
	Female	Male	p-value	Female	Male	p-value	Female	Male	p-value
Month 0	13.0	9.0	<0,001	13.0	10.0	0.1	15.0	11.0	0.027
Month 3	4.0	3.0	0.4	2.5	2.0	0.4	1.0	1.0	0.8
Month 6	2.0	2.0	0.7	1.0	1.0	0.7	0.0	1.0	0.2
Month 12	2.0	1.0	0.2	0.0	0.0	0.3	0.0	1.0	0.6
Month 18	2.0	1.0	0.2	1.0	1.0	0.7	0.0	0.0	0.7
Month 24	2.5	1.0	0.2	1.0	0.0	0.6	0.0	0.5	0.4
	IL-23 inhibitors			IL-12/23 inhibitor					
	Female	Male	p-value	Female	Male	p-value			
Month 0	13.5	9,3	0.6	7,5	7	0.049			
Month 3	0.5	0.0	0.6	0.0	0.0	0.8			
Month 6	0.0	0.0	0.5	0.0	0.0	0.4			
Month 12	0.0	0.0	0.6	0.8	0.0	0.1			
Month 18	0.0	0.0	0.4	0.0	0.0	0.1			
Month 24	0.0	0.0	0.3	1.0	0.0	0.043			

The provided data represent median values with bold indicating statistical significance.

Table SVII. Descriptive statistics considering DLQI between the sex.

		Number of patients	Mean	Standard dev	Minimum	1st quantile	Median	3rd quantile	Maximum
Male	Visit 1	470	10,65	7,17	0	5	10	16	30
	Visit 2	371	4,14	5,07	0	0	2	6	27
	Visit 3	328	3,05	4,41	0	0	1	4,25	23
	Visit 4	240	2,51	4,13	0	0	1	3	25
	Visit 5	174	1,94	3,17	0	0	1	2	16
	Visit 6	154	1,99	3,57	0	0	1	2	22
Female	Visit 1	278	13,39	7,80	0	7	13	19	30
	Visit 2	208	4,86	5,65	0	0	3	8	26
	Visit 3	159	3,42	5,07	0	0	1	5	25
	Visit 4	126	2,67	4,50	0	0	1	3	29
	Visit 5	91	2,30	2,98	0	0	1	3	11
	Visit 6	76	2,96	4,02	0	0	1	5	24

Table SVIII. Descriptive statistics considering DLQI between the sex for the non-biologic patient group (methotrexate, fumarates, retinoids, cyclosporine and apremilast).

		Number of patients	Mean	Standard dev	1st quantile	Median	3rd quantile
Male	Visit 1	202	9,86	6,79	4	9	15
	Visit 2	138	5,05	5,29	1	3	7
	Visit 3	121	3,39	4,57	0	2	5
	Visit 4	79	2,78	3,84	0	1	4
	Visit 5	48	2,31	3,05	0	1	3
	Visit 6	43	2,74	4,96	0	1	2,5
Female	Visit 1	129	12,87	7,42	7	13	18
	Visit 2	83	5,43	4,92	1	4	9
	Visit 3	52	3,38	3,97	0	2	5
	Visit 4	45	3,38	4,06	0	2	6
	Visit 5	28	3,21	3,51	0	2	6
	Visit 6	22	3,91	5,51	0	2,5	5,5

Table SIX. Descriptive statistics considering DLQI between the sex for the TNF- α patient group (adalimumab, certolizumab, etanercept, golimumab, infliximab).

		Number of patients	Mean	Standard dev	1st quantile	Median	3rd quantile
Male	Visit 1	94	10,77	7,97	4,25	10	16
	Visit 2	81	4,54	6,18	0	2	7
	Visit 3	67	3,91	5,57	0	1	6
	Visit 4	51	3,02	5,38	0	0	4,5
	Visit 5	39	3,26	4,79	0	1	4,5
	Visit 6	32	2,12	3,40	0	0	3
Female	Visit 1	49	13,12	8,31	6	13	19
	Visit 2	40	5,25	6,50	1	2,5	7
	Visit 3	36	4,17	5,94	0	1	7
	Visit 4	25	2,12	5,86	0	0	1
	Visit 5	18	1,94	2,62	0	1	2,75
	Visit 6	17	2,47	3,00	0	1	4

Table SX. Descriptive statistics considering DLQI between the sex for IL-17 inhibitor patient group (secukinumab and ixekizumab).

		Number of patients	Mean	Standard dev	1st quantile	Median	3rd quantile
Male	Visit 1	71	10,89	7,48	4	11	17
	Visit 2	62	3,32	4,34	0	1	6
	Visit 3	62	2,81	3,99	0	1	4,75
	Visit 4	48	2,44	4,23	0	1	3
	Visit 5	27	1,30	2,37	0	0	1
	Visit 6	28	1,39	2,30	0	0,5	2
Female	Visit 1	37	14,32	7,98	8	15	20
	Visit 2	29	3,66	5,77	0	1	6
	Visit 3	26	1,73	3,58	0	0	1
	Visit 4	23	1,57	2,41	0	0	2,5
	Visit 5	20	1,50	2,26	0	0	3
	Visit 6	16	1,56	3,05	0	0	1,25

Table SXI. Descriptive statistics considering DLQI between the sex for IL-23 inhibitor patient group (tildrakizumab, risankizumab and guselkumab).

		Number of patients	Mean	Standard dev	1st quantile	Median	3rd quantile
Male	Visit 1	50	13,20	7,33	9,25	13	18,75
	Visit 2	46	2,93	3,90	0	1,5	4
	Visit 3	38	2,45	3,51	0	1	3,75
	Visit 4	26	1,85	3,40	0	0	2
	Visit 5	21	1,05	1,43	0	0	2
	Visit 6	13	0,62	0,87	0	0	1
Female	Visit 1	28	13,79	8,23	10,25	13,5	20
	Visit 2	27	3,85	5,49	0,5	2	5
	Visit 3	20	2,75	3,82	0	1	3,5
	Visit 4	17	1,71	2,71	0	1	2
	Visit 5	13	1,77	2,68	0	1	2
	Visit 6	7	3,00	3,83	0	1	5

Table SXII. Descriptive statistics considering DLQI between the sex for IL-12/23 inhibitor patient group (ustekinumab).

		Number of patients	Mean	Standard dev	1st quantile	Median	3rd quantile
Male	Visit 1	53	10,74	6,1	7	11	14
	Visit 2	44	3,02	3,5	0	1	4
	Visit 3	40	1,57	2,35	0	1	2
	Visit 4	36	1,78	3,0	0	1	2
	Visit 5	39	1,13	1,72	0	1	1
	Visit 6	38	1,95	3,08	0	1	2
Female	Visit 1	35	14,37	8,2	7,5	15	21,5
	Visit 2	29	4,86	6,45	0	2	6
	Visit 3	25	4,76	7,3	0	1	6
	Visit 4	16	4,19	6,48	0,75	1,5	4,25
	Visit 5	12	2,67	3,37	0	1	4,25
	Visit 6	14	3,64	3,3	1	3,5	5,75